Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Abstract

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00340 JCO Precision Oncology no. 7 (2023) e2200340. Published online January 12, 2023. Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding Mir Lim , MD1xMir LimSearch for articles by this author; Patrick T. Lynch , MD1xPatrick T. LynchSearch for articles by this author; Xiaochen Bai, PhD2xXiaochen BaiSearch for articles by this author; and David Hsiehchen , MD1xDavid HsiehchenSearch for articles by this author Show More 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX2Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX https://doi.org/10.1200/PO.22.00340 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTD.H. was supported by a Cancer Prevention and Research Institute of Texas Early Clinical Investigator Award.AUTHOR CONTRIBUTIONSConception and design: David HsiehchenCollection and assembly of data: Mir Lim, Xiaochen Bai, David HsiehchenData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).No potential conflicts of interest were reported.